Embecta (EMBC) said Friday it is expanding its partnership with Direct Relief, a charitable insulin provider in the US, to continue to provide pen needle and insulin syringe to the needy through 2026.
The company said it has already donated about 15 million units of pen needles and insulin syringes to Direct Relief.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.